Pierre-André Wicker

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.

Pharmaleads SA specializes in the detection, inhibition and modulation of proteases involved in human diseases. It designs and develops analgesic drugs with the aim to revolutionize the treatment of severe pain, with no side effects. The firm's products include high fluorescence substrates for proteases, substrates for BoNT quantification, and EzyBot, a field kit for botulinum toxin detection. The company was founded in 2000 by Bernard Roques and Marie-Claude Fournié-Zaluski and is headquartered in Paris, France.